As policy dynamics accelerate across federal and state channels, manufacturers must prepare for multiple scenarios and align internal planning. Key readiness priorities for 2026.
Design research payers can use: focus on real-world outcomes, durability, and total cost of care; bring payer input in early and often; and pressure-test access levers pre-launch. Turn strong science into coverage, reimbursement, and measurable ROI.
In this featured presentation from the 2025 Evidence 360 Summit, Magnolia Market Access’s Beni Turner explores how RWE can be strategically integrated across the product lifecycle to drive more effective pricing and access outcomes.
This case study explores how a small pharmaceutical company utilized real-world evidence (RWE) to calculate the national incidence of a rare disease.
On May 12, 2025, President Trump signed an executive order with the potential to significantly change the U.S. drug pricing and distribution system. Here is what we know about the Administration’s new Most Favored Nation (MFN) policy:
At Magnolia Market Access, we see frailty as a key variable in evidence generation and access strategy. Ahead of ISPOR 2025, we sat down with Mike Murphy to discuss Magnolia’s latest research using administrative claims data to evaluate frailty indices.
Magnolia Market Access analyzed a potential sliding fee scale policy, adjusting patient cost-sharing for 340B-dispensed drugs, to understand implications on out-of-pocket costs for 340B patients.
Magnolia Market Access analyzed a potential sliding fee scale policy, adjusting patient cost-sharing for 340B-dispensed drugs, to understand implications on out-of-pocket costs for 340B patients.
A biopharma company engaged Magnolia Market Access and sister company, 81qd, to collect data and segment provider and payer entities to identify key decision
makers for a novel cardiology treatment.
A large pharmaceutical company needed to
demonstrate the potential cost savings of placing a new drug on payer formularies.